Haya Therapeutics Unveils CRISPR-Based Approach to Target Non-Coding DNA in Fibrotic Disease
Haya Therapeutics, a biotechnology startup, has announced a novel gene-editing strategy to treat fibrotic diseases by targeting non-coding regions of the genome, according to a report by *Chemical & Engineering News* (C&EN). The company’s approach, which leverages CRISPR-Cas9 technology, aims to address mutations in “dark genome” sequences—regions previously thought to lack functional significance.
Understanding the Dark Genome
The term “dark genome” refers to non-coding DNA, which constitutes approximately 98% of the human genome. While these regions were once considered “junk DNA,” recent research has revealed their potential role in regulating gene expression. Fibrotic diseases, such as idiopathic pulmonary fibrosis and liver cirrhosis, involve abnormal tissue scarring, often linked to genetic factors in these non-coding areas.
CRISPR’s Role in Targeting Non-Coding DNA
Haya Therapeutics’ method focuses on editing specific non-coding sequences to modulate the activity of genes associated with fibrosis. Unlike traditional CRISPR applications that target protein-coding genes, this approach seeks to correct regulatory elements that may contribute to disease progression. A 2023 study in *Nature Biotechnology* highlighted the growing interest in non-coding DNA as a therapeutic target, though challenges remain in identifying precise mechanisms.
Challenges and Opportunities
Experts caution that targeting non-coding DNA is complex. “The functional consequences of edits in these regions are not always predictable,” said Dr. Emily Zhang, a geneticist at the Broad Institute, in an interview. However, Haya’s strategy aligns with broader trends in precision medicine, where therapies are increasingly tailored to genetic profiles. The company has partnered with academic researchers to validate its approach, with preliminary trials expected to begin in 2024.
Why This Matters
Fibrotic diseases affect over 400 million people globally, with limited treatment options. If successful, Haya’s work could pave the way for therapies addressing underlying genetic causes rather than just symptoms. This aligns with a 2022 initiative by the National Institutes of Health (NIH) to prioritize non-coding DNA research, underscoring its potential impact.
Looking Ahead
While Haya Therapeutics’ project is still in early stages, its focus on the dark genome reflects a shift in biotechnology toward exploring previously overlooked genetic elements. As CRISPR tools advance, the ability to manipulate non-coding regions may unlock new avenues for treating a range of genetic disorders.
Worth a look